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Abstract: Tolperisone (2-methyl-1-(4-methylphenyl)-3-piperidin-1-ylpropan-1-one hydro-chloride) was introduced in the 
clinical practice more than forty years ago and is still evaluated as a widely applicable compound in pathologically ele-
vated skeletal muscle tone (spasticity) and related pains of different origin. In the present review, basic pharmacodynamic 
effects measured on whole animals, analyses of its actions on cell and tissue preparations and molecular mechanism of ac-
tion on sodium and calcium channels are summarized as recently significantly new data were reported.  
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channels, spasticity, Tolperisone. 
INTRODUCTION 
The compound (Fig. 1) was synthesized as early as in 
1956 as a result of research activity in Gedeon Richter 
Pharmaceutical Works. Tolperisone is an aryl alkyl ?-
aminoketone with an asymmetric carbon atom ? to the car-
bonyl group.The dextrorotatory enantiomer was reported less 
effective, however no detailed analyses of the enantiomers 
are available [1]. The first pharmacological evaluation of its 
central anti-nicotine action without parasympatholythic ac-
tivity was reported in 1958 by Nádor and Pórszász [2]. The 
first detailed characterization of its interneuron blocking 
activity on cats and rats was published by Pórszász et al. 
establishing that the compound is a specific inhibitor of the 
central nervous multineuronic synapses, capable to normal-
ize the hyperreflexia elicited by intravenously administered 
20 ?g/kg strychnin which acts by blocking the collateral neu-
rons of Renshaw, the inhibitory interneurons in the gray mat-
ter of the spinal cord [3]. 
Tolperisonum hydrochloride (Mydeton, Mydocalm) was 
introduced in the clinical practice in the 1960’s with the pri-
mary indication to control muscular hypertonia. Nowadays it 
is in the market under several names (Musclex, Musolax, 
Mydosone, Tolson Plus, A-Calm, Besnoline F, Biocalm, 
Conspin, Lexaton, Miodom, Muscalm, Musocalm, 
Myderison, Myolax, Myoxan, Nichiperisone, Perilax, Quali-
Docalm, Risocalm, Soneriper, Tanderon, Tolcalm, Tolesin, 
Tolfree, Tolperis, Tolpidol, Tolson, Topee, Toperin, 
Topeson, Topownan, Torimaron, Userm, Viveo). Within a 
few years following its introduction in clinical practice sev-
eral reports were published on its acute and long-term effi-
cacy in different rheumatological, orthopaedic, traumatologi-
cal, neurological disorders (e.g. cerebral palsy, traumatic 
brain injury, stroke,multiple sclerosis and different forms 
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of spinal cord injury), however only seven randomized clini-
cal studies have been published.  
 
   
Fig. (1). Chemical structure of tolperisone. 
 
CLINICAL TRIALS ON TOLPERISONE 
The first randomized clinical trial on its efficacy and 
safety (Mydocalm, 300 mg, p.o. for 21 days) in the treatment 
of painful reflex muscle spasm in a prospective double-blind, 
placebo-controlled trial was published by Pratzel et al. [4] It 
was concluded that tolperisone hydrochloride represents an 
effective and safe treatment of painful reflex muscle spasm 
without the typical side effects of centrally active muscle 
relaxants.  
In a randomized double blind and placebo controlled trial 
Mydocalm (150 mg twice daily for 12 weeks) was found to 
be a well tolerated and efficacious drug [5]. 
In a placebo-controlled double-blind clinical trial carried 
on a total of 72 healthy young adults single and repeated 
doses of Mydocalm (50 and 150 mg for 8 days) did not cause 
any sedation or impaired reaction times [6].  
In a double-blind randomized crossover control study Ba-
jaj et al. found that prophylactic intake of tolperisone hydro-
chloride (150 mg three times daily for 8 days) provides no 
relief to pain in course of post-exercise muscle soreness but 
results in reduction in isometric force [7].  
The randomised, double-blind, placebo-controlled three-
way cross-over study of tolperisone hydrochloride (300 mg, 
p.o.) and pridinol mesilate (8 mg, p.o.) on experimental jaw-
muscle pain and jaw-stretch reflexes was studied by Svens-
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son et al. It was concluded that, tolperisone provides a sig-
nificant reduction in the perceived intensity of experimental 
jaw-muscle pain whereas had no effect on the short-latency 
jaw-stretch reflex [8]. 
Efficacy and safety of tolperisone (300-900 mg daily for 
12 weeks) in the treatment of stroke-related spasticity in a 
randomized, double-blind, placebo-controlled, multicenter 
study with parallel groups was studied by Stamenova et al. 
[9]. Tolperisone reduced the mean Ashworth Score by a  
p < 0.0001 significance compared to the placebo group. Ad-
verse events occurred less often on active treatment than on 
placebo and were mostly of mild-to-moderate intensity. Find-
ings demonstrated the efficacy and excellent tolerance of 
tolperisone in the treatment of spastic hypertonia following 
cerebral stroke. It was also suggested that an individual dose 
titration which may exceed the recommended maximum dose 
of 450 mg daily results in optimized therapeutic benefit. 
In a prospective, open-labelled, non-comparative, multi-
centre observational, post marketing surveillance study con-
ducted at 174 participating orthopaedic care centres across 
India 920 patients with painful muscle spasm associated with 
degenerative or inflammatory conditions were studied. 
Tolperisone (150 mg thrice daily for 7 days, p.o.) resulted in 
significant improvements (p < 0.0001) in Likert scale. No 
sedation was reported by any patient during study period and 
the incidence of common adverse effects like nausea, gastric 
irritation was less than 2% [10]. 
In a multicentric, randomized, comparative clinical trial, 
250 eligible patients, with spasm of spinal muscles with 
acute or relapsing low back pain, of moderate to severe in-
tensity and no finding of severe spinal diseases were ran-
domly assigned to receive 150 mg of tolperisone thrice daily 
or 8 mg of thiocolchicoside twice daily for 7 days. The im-
provement in articular excursion on Lasegue’s maneuver was 
significantly greater on day 3 with tolperisone as compared 
to thiocolchicoside. The reduction in finger-to-floor distance 
score was greater on day 7 with tolperisone.The improve-
ment in pain score at rest and on movement was significantly 
greater with tolperisone [11]. 
In the recently published consensus documented by 
Spanish Society of Neurology, Scottish Intercollegiate 
Guidelines Network system and German Neurological Soci-
ety on recommendations for treatment of key symptoms such 
as spasticity in patients with multiple sclerosis tolperisone 
(as well as dantrolene and benzodiazepines) was evaluated as 
“not well documented” [12].  
Tolperisone has been widely and effectively used in the 
clinical practice, however its exact mechanism of action has 
been not fully understood [13]. This might go back to the fact, 
that mechanisms involved in the pathophysiology of spastic-
ity, one of several components of the upper motor neurone 
syndrome, have been and still are not sufficiently revealed 
[14]. 
PHARMACOLOGICAL DATA OF TOLPERISONE 
ON WHOLE ANIMALS 
When monosynaptic and polysynaptic ventral root re-
flexes, the dorsal root potential and the dorsal root reflex 
were recorded in spinal cats, tolperisone (2.5-10 mg/kg i.v.) 
dose-dependently inhibited both ventral root reflexes and the 
dorsal root reflex, slightly prolonged the dorsal root potential 
without affecting the amplitude. However its effects were 
unique when compared its effects to baclofen and benzodi-
azepines (midazolam,diazepam) as these compounds abol-
ished the monosynaptic reflex and only partially inhibited 
the polysynaptic reflex [15]. 
Participation of local anesthetic action (membrane stabi-
lizing effect) in spinal reflex inhibition produced by tolperis-
one was examined by comparing the local anesthetic effects, 
the in situ depressant effects on muscle afferent discharges 
and the depressant effects on spinal reflexes in rats. The or-
der of reducing afferent discharges by the drugs correspond 
on of their conduction blocking activities in the isolated sci-
atic nerve of rats. Membrane-stabilizing action in rats, spinal 
reflex inhibition and conduction blocking activity in the iso-
lated sciatic nerve was reported by Ono et al. [16].  
In anesthetized and laminectomized mice in the lumbo-
sacral region, tolperisone transiently while baclofen long-
lastingly inhibited the amplitudes of monosynaptic reflex 
potential giving further evidence on tolperisone’s membrane 
stabilizing activity with different mechanism of action of 
baclofen [17]. 
Tolperisone was reported to reversibly inhibit tonic 
periodontal massateric reflex in rats [18] and tonic mastica-
tory neck reflex in patients [19]. 
In anesthetized intact rats tolperisone (5-10 mg/kg. i.v.) 
dose-dependently inhibited the group II flexor reflex reach-
ing peak of about 50 and 75% at 2 min after administration 
and significant inhibition was observed within 30 min. The 
effects of chlorpromazine (0.2 and 0.6 mg/kg, i.v.) reached 
peaks of 50 and 80 %, respectively, at 5min after administra-
tion and significant inhibition was observed within 40 min. 
Baclofen (0.6, 1.3 and 2.5 mg/kg, i.v.) showed qualitatively 
and quantitatively similar effects. It was concluded that 
tolperisone, as a centrally acting muscle relaxant depresses 
group II flexor reflex by inhibiting descending noradrenergic 
tonic facilitation within the spinal cord [20].  
Sakaue et al. [21] compared the effects of different drugs 
with sodium channel blocking effect used in the clinical 
practice for neuropathic pain on acute thermal and mechani-
cal nociception. The following compounds were tested and 
assessed using the plantar and tail pressure tests: the antiepi-
leptic carbamazepine and phenytoin, the centrally acting 
muscle relaxants tolperisone, zonisamide and eperisone, the 
local anaesthetic lidocaine and the ?-opioid receptor agonist 
morphine. Morphine produced analgesic effect both on acute 
thermal and mechanical nociception, while the other com-
pounds including tolperisone (3-30 ?mol/kg, s.c.) showed 
dose-dependent preferential elevation of the threshold for 
thermal nociception. This analgesic effect was correlated to 
their sodium channel blocking property. It was also shown in 
the sciatic nerve preparation isolated from mice that mexilet-
ine, lidocaine, eperisone, and tolperisone impaired the 
propagation of low frequency action potentials, while car-
bamazepine, phenytoin and zonisamide action was obvious 
on higher frequency action potentials. Tolperisone was found 
to inhibit action potential propagation on both A- and C-
fibers of rat sciatic nerve [22]. 
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Muscle relaxant effect of toleprisone on spinal reflexes 
was first evidenced by Farkas et al. in1989, [15] however 
detailed analysis on the spinal reflex machinery between the 
stimulated dorsal root and the ventral root conveying efferent 
discharges in the rat spinal cord both in vitro and in vivo, in 
comparison with the local anesthetic lidocaine was per-
formed by Kocsis et al. [23]. On isolated hemisected spinal 
cord preparation dorsal root stimulation-evoked ventral root 
potentials (DR-VRP) were recorded from the L5 ventral 
root. Tolperisone (50-400 ?M) and its analogues (eperisone, 
lanperisone, inaperisone and silperisone) as well as lidocaine 
(200-800 ?M) caused concentration-dependent depression of 
all studied components of DR-VRP. Significant attenuation 
of monosynaptic reflex potentials, afferent fiber potentials 
and excitatory postsynaptic potential were also produced by 
all the compounds studied. 
 In the in vivo spinal reflex study on decerebrated 
laminectomized rats all the compounds studied significantly 
attenuated monosynaptic, disynaptic, and polysynaptic reflex 
potentials. Tolperisone and eperisone had practically identi-
cal effects in the relative sizes of the effects and on the three 
different ventral root reflex components, however, peak  
effects of tolperisone were greater for all of the three com-
ponents. The profile of lidocaine was different, producing 
weaker depressant effect on monosynaptic reflex potentials 
than on polysynaptic reflex potentials. Studying the afferent 
nerve conduction in vivo, possibility of a local anesthetic-
type inhibition of afferent nerve conduction to the reflex 
inhibition following systemic silperisone, tolperisone, and 
lidocaine was compared. Tolperisone and silperisone left 
afferent nerve conduction practically unchanged, while lido-
caine was slightly effective. 
In decerebrated rats and mice tolperisone (10 mg/kg, i.v. 
or p.o.) and its analogues (eperisone and lanperisone) dose 
dependently depressed the muscle tone in the ?-rigidity and 
?-rigidity preparations, and the depression reached its 
maximum at 10 min following administration. Among the 
compounds studied only tolperisone decreased the frequency 
of muscle spindle discharges [24]. 
In the Spared Nerve Injury Model (SNIM) of neuropathic 
pain induced in rats effectiveness of tolperisone (10 mg/kg, 
i.p.) on thermal hyperalgesia and cold-allodynia evoked by 
various stimuli was similar to phenytoin (20 mg/kg) which is a 
standard compound as a sodium channel blocker. Results em-
phasise the concept that blockade of sodium channels by 
tolperisone may be beneficial for treatment of neuropathic 
pain [25]. 
ANALYSES OF TOLPERISONE’S ACTIONS ON 
CELL AND TISSUE PREPARATIONS  
The first data on tolperisone’s effect on ionic currents 
was published by Hinck and Koppenhöfer [26]. Further 
analysis of tolperisone’s mechanism of effect using single 
intact Ranvier nodes of the toad Xenopus by means of the 
Hodgkin-Huxley formalism [27] showed that tolperisone 
(100 ?M) decreased sodium permeability by about 50% in a 
potential-independent manner while other parameters of the 
sodium system remained unchanged. Potassium permeability 
was decreased only at strong depolarizing potentials and at 
week depolarization potential a significant increase in potas-
sium permeability could be seen. All the effects were com-
pletely reversible. Apparent dissociation constants of  
0.06 mmol/l and 0.32 mmol/l for sodium and potassium, 
respectively, were calculated. These findings clearly showed 
that tolperisone has fundamentally different effect on voltage 
gated sodium channel than local-anaesthetic compounds.  
Quasthoff et al. [22] applied a new and elegant electro-
physiological method for in vitro nerve compound action 
potential (CNAP) recordings of the isolated rat sural nerve 
including sodium channels functionally expressed in 
Xenopus oocytes. Two different Na
+
 channel subtypes ?-
subunits were functionally expressed, Nav1.6, that is mainly 
responsible for the A-fibre CNAP and the tetrodotoxin- re-
sistant Nav1.8, mainly expressed in C-fibres [28]. Addition 
of tolperisone (100 mM) to the bath solution resulted in a 
fast and significant reductions both in myelinated A- and 
unmyelinated C-fibre compound action potential giving fur-
ther evidence that tolperisone is an effective inhibitor of 
voltage-dependent sodium channels.  
As tolperisone is structurally related to the sodium chan-
nel antagonists local anesthetics (lidocaine and procaine) 
[29] Hofer et al. [30] compared the acute effect of tolperis-
one and lidocaine on seven different isoforms of the voltage- 
dependent sodium channels (Nav1.2, Nav1.3, Nav1.4, 
Nav1.5, Nav1.6, Nav1.7, and Nav1.8 isoforms) expressed in 
the Xenopus laevis oocyte expression system. Sodium cur-
rents were recorded with the two electrode voltage clamp 
technique. Kinetic analysis of cumulative dose response 
curves showed that there were marked differences between 
the effects of the two drugs on identical isoforms, significant 
for the neuronal Nav1.6, Nav1.7 and Nav1.8 isoforms. The 
extent of use-independent (tonic) block (connected to pain 
treatment) on the same isoform was significantly stronger for 
tolperisone (Nav1.2, Nav1.3, Nav1.7 and Nav1.8). Both 
compounds affected recovery from inactivation. Tolperisone 
had no prolongating effect on fast recovery process, however 
lidocaine had prolongation of the time constant of the fast 
recovery process for the Nav1.3, Nav1.5, and Nav1.7 iso-
forms (characteristic for local anaesthetics). 
Effects of tolperisone, silperisone, eperisone, and lido-
caine on voltage-gated sodium currents on medium-sized 
dorsal root ganglion cells acutely dissociated from 6-day-old 
male rats was analysed by Kocsis et al. [23]. All the com-
pounds studied inhibited peak sodium currents evoked by 
step depolarizations in a concentration-dependent manner, 
caused concentration-dependent shifts of the control inacti-
vation curves toward the more hyperpolarized membrane 
potentials, but they also decreased the maximum available 
current. However at the IC50 concentrations for sodium 
channel blockade of the substances studied their N-type cal-
cium channel blocker effect was very weak. 
Comparing the effects of eperisone (analogue of tolperis-
one) and different Ca-antagonists on the basilar artery of the 
guinea pig [31] it was suggested that tolperisone may have 
Ca
2+
 channel antagonist effect. Novales-Li studied the effects 
of tolperisone, eperisone and isoperisone on the calcium cur-
rent in an identified neurone of the snail Achatina fulica un-
der voltage clamping [32, 33]. It was found that all the three 
drugs inhibited calcium current dose dependently without 
affecting activation time and shifted the steady state inactiva-
tion curves in the hyperpolarizing direction. Data suggested 
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We can conclude that the mechanism of action of the 
centrally acting muscle relaxant effect of tolperisone is re-
lated to its depressive effect on voltage-gated sodium and on 
a lesser extent on N-type calcium channels.  
Tolperisone’s therapeutic effect is interpretable by its ef-
fective inhibiting action on afferent nociceptive input to the 
spinal cord, attenuation of spinal reflexes and inhibition of 
descending reticulo-spinal projections. However the effects 
of tolperisone in the brain were only recently analyzed [34, 
35] using the robust, non-invasive technique of magnetic 
resonance imaging (MRI) for the direct observation of acti-
vation patterns evoked by tolperisone. The effect of tolperis-
one on the resting brain activity was studied in anaesthetized 
Wistar rats. To measure activation in the brain evoked by 
tolperisone the blood oxygen level dependent (BOLD) 
method of functional MRI (fMRI) was used. Effects of 
tolperisone were evaluated in prefrontal cortex, cingular cor-
tex, primary somatosensory cortex, forelimb region, secon-
dary somatosensory cortex, insular cortex,ventral postero-
lateral thalamic nucleus. Tolperisone (20 mg/kg i.p.) caused 
only non significant direct effect in the BOLD answer fol-
lowing its administration. However electrical stimulation of 
the rat forepaw caused massive BOLD increase in prefrontal 
cortex, cingular cortex , insular cortex, somatosensory cortex 
and thalamus and tolperisone almost completely prevented 
these provoked BOLD responses. Effect of tolperisone was 
most pronounced in the brain areas involved in pain sensa-
tion (prefrontal cortex, insula, thalamus and secondary soma-
tosensory cortex). It is worth mentioning that lidocaine  
(10 mg/kg i.v.) was reported to rather increase painful train 
stimuli evoked BOLD responses in the brain [36], while an 
increased inhibitory effect of lidocaine (3 mg/kg i.v.) in the 
spinal cord on painful train stimuli evoked BOLD response 
increase was also reported [37]. 
There is a renewing interest in determination of the pre-
cise binding site of tolperisone on voltage-gated sodium 
channel. In a molecular modeling study [29] it was con-
cluded that tolperisone and lidocaine can attach to identical 
protein binding sites, however no direct competition binding 
studies were still published. In the first pharmacological 
evaluation of tolperisone [2] tolperisone was shown to have 
central anti-nicotine action without parasympatholythic ac-
tivity. On rat cortical synaptosomal preparation nicotinic 
acetylcholine receptor binding measured by [
3
H]BTX bind-
ing was inhibited dose dependently by tolperisone (IC50 40.9 
± 2.5 ?M) and related centrally acting muscle relaxants (sil-
perisone,eperisone, lanperisone,inaperisone) while lidocaine 
was one order of magnitude less potent [23]. 
SUMMARY 
Tolperisone is a widely used compound in the clinical 
practice for pathologically elevated skeletal muscle tone 
 
Fig. (2). Mechanism of action of Tolperisone. (Abbreviations: DR: Dorsal root, DRG: Dorsal root ganglion, VR: Ventral root, SN: Spinal 
nerve, DR-VRP: Dorsal root stimulation-evoked ventral root potential). 
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(spasticity) and related pains. Tolperisone is a centrally act-
ing muscle relaxant agent blocking spinal segmental reflex 
activity (Fig. 2). Recent evaluations of its mechanism of ac-
tion revealed that the compound inhibits sodium channels 
and has N-type calcium channel blocking activity as well 
both in vitro and in vivo. Tolperisone is a specific inhibitor 
of the monosynaptic reflexes and only partially inhibits the 
polysynaptic reflexes. Its effects are unique compaired to 
baclofen and benzodiazepines, as it dose-dependently de-
presses group II flexor reflex by inhibiting descending 
noradrenergic tonic facilitation within the spinal cord. 
Tolperisone effectively inhibits afferent nociceptive input to 
the spinal cord, attenuates spinal reflexes and inhibits de-
scending reticulo-spinal projections.Tolperisone inhibits 
action potential propagation on both in myelinated A- and in 
unmyelinated C-fibers and causes depression of all dorsal 
root stimulation-evoked ventral root potentials. Tolperisone 
has specific inhibitory effect on use-independent sodium 
channels (Nav1.2, Nav1.3, Nav1.7 and Nav1.8) connected to 
pain, which is a significant difference compared to lido-
caine’s effect on sodium channels. Tolperisone’s effect was 
most pronounced in the brain areas involved in pain sensa-
tion (prefrontal cortex, insula, thalamus and secondary soma-
tosensory cortex). Tolperisone hydrochloride represents an 
effective and safe treatment of painful reflex muscle spasm 
without the typical side effects of centrally active muscle 
relaxants.  
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